

## WEDNESDAY, 14<sup>th</sup> OCTOBER 2009 COMMENCING 10.30 AM (UNTIL 3.00 PM APPROX)

AT THE ANGEL HOTEL, ABERGAVENNY, NP7 5EN

## **AGENDA**

		Enclosure
1.	Welcome and introduction	
2.	Apologies	
3.	Declarations of interest	
4.	Chairman's report (verbal update)	
5.	Minutes of previous meeting - Matters arising	1/AWMSG/1009
6.	Appraisal 1: Mecasermin (Increlex <sup>®▼</sup> ) For the treatment of growth failure in children and adolescents with severe primary deficiency (low blood levels) of a hormone, insulin-like growth factor-1 (IGF-1)	<b>2</b> /AWMSG/1009 Appendices
7.	Appraisal 2: Methoxy polyethylene glycol-epoetin beta (Mircera <sup>®</sup> <sup>▼</sup> ) For the treatment of symptomatic anaemia associated with chronic kidney disease	<b>3</b> /AWMSG/1009 Appendices
8.	AWMSG Constitution update (for information)	4/AWMSG/1009
9.	Updated supplementary information Appraising life-extending, end of life treatments	5/AWMSG/1009
10.	Informing Healthcare	6/AWMSG/1009
11.	Development of a Drug Formulary System for Wales	7/AWMSG/1009
12.	Date of next meeting - Wednesday, 16 <sup>th</sup> December 2009 at The Angel Hotel, Abergavenny. The February meeting has been re-scheduled to 3 <sup>rd</sup> March 2010	